FDA批准adrabetadex用于治疗婴儿型尼曼-匹克病C型
FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder
FDA于本周二批准adrabetadex(Lembaz)注射液用于婴儿型尼曼-匹克病C型(NPC)患者,适用于神经系统症状始于6岁前且体重至少15磅的成人和儿童。
原文明确给出FDA批准事项、生存获益数据和黑框警告,读者可据此评估对该罕见病的实际价值与用药安全关注点。
— Adrabetadex-treated patients with Niemann-Pick disease type C lived longer than external controls
November 18, 2026 • 2 min read
The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder.
Indicated for adults and children weighing at least 15 lb whose neurological symptoms began before age 6 years, adrabetadex targets the cholesterol that accumulates inside brain cells and drives progressive neurological damage.
The approval was supported by survival data from 36 patients across three clinical studies and an expanded access program, where treatment with adrabetadex was associated with a 55% reduction in the risk of death compared with matched external controls.
Median overall survival was 8.5 years among patients treated with adrabetadex compared with 4.9 years in the control group. Longer survival was observed with adrabetadex regardless of whether patients were also taking miglustat, a therapy commonly used off-label for NPC.
"Niemann-Pick disease type C is incredibly devastating, gradually robbing those who have the condition of all of their abilities, leaving them debilitated and cutting short their lives far too soon. Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical," said study investigator Elizabeth Berry-Kravis, MD, PhD, of Rush University Medical Center in Chicago, in a press release from drugmaker Beren Therapeutics.
Adrabetadex "gives children more time to be children, more time with their families, more time to live life," she added.
Affecting roughly one in 150,000 people, NPC is an inherited lysosomal storage disorder that impairs the body's ability to transport and metabolize cholesterol and other lipids within cells. As these fats build up over time, patients experience progressive neurodegeneration, gradually losing motor control, coordination, and the ability to swallow.
Roughly half of the Americans living with NPC -- about 475 children -- have infantile-onset NPC, the most severe and rapidly progressive form of the disease, in which neurological manifestations develop before age 6 years. Those whose symptoms emerge before age 2 years have a mean age at death of about 5.6 years, while those with symptom onset between ages 2 and 5 years have a mean age at death of about 13.4 years.
Two other therapies are approved for NPC -- arimoclomol (Miplyffa) and levacetylleucine (Aqneursa) -- but neither has been associated with a reduced risk of death, and both have age or weight restrictions that limit access for some pediatric patients.
The most common side effects with adrabetadex (reported in 25% or more of patients in a clinical trial) were hearing impairment, ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. The prescribing information warns of ataxia and fatigue, and carries a boxed warning regarding hearing impairment, including permanent hearing loss.
"A comprehensive hearing evaluation should be performed on patients before starting Lembaz and regularly throughout treatment, and dose adjustments may be needed based on the results of these evaluations," the FDA advised.
A trained healthcare provider administers adrabetadex as an intrathecal injection every 2 weeks.
来源:MedPage Today · medpagetoday.com